Change the keyword or sentiment above, then click Apply.
Thursday, 03 Sep 20262 updates
↔ AI sentiment: Neutral
61% confidence
Suven Life Sciences Advances Alzheimer's Drug; Phase-3 Results by May 2027
Suven Life Sciences completes patient enrollment for global Phase-3 study of Masupirdine (SUVN-502) for Alzheimer's agitation.
Topline results expected by May 2027; Masupirdine shows potential with favorable efficacy and tolerability profile.
Source: BSE
↗ AI sentiment: Bullish
77% confidence
Suven Life Sciences: Completes Enrollment Of 424 Patients In Global Phase-3 Study Of Masupirdine For Alzheimer's Agitation, Results Expected By May 2027.
Tuesday, 25 Aug 20261 update
↔ AI sentiment: Neutral
88% confidence
Suven Life OKs All Resolutions at 37th AGM
Suven Life Sciences Ltd conducted its 37th AGM on Aug 25, 2026 via VC/OAVM.
All resolutions, including financials adoption and director appointments, were passed with requisite majority.
Source: BSE